# Study of AK156 in Primary Osteoporosis Patients

> **NCT01522521** · PHASE3 · COMPLETED · sponsor: **Asahi Kasei Therapeutics Corporation** · enrollment: 600 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** AK156
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01522521
- **Lead sponsor:** Asahi Kasei Therapeutics Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01522521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01522521, "Study of AK156 in Primary Osteoporosis Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01522521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*